Figure 1A
Use of potentially nephrotoxic antiretrovirals at baseline: Exposure to ARVs at/before baseline

Figure 1B
Use of potentially nephrotoxic antiretrovirals at baseline: Median exposure to ARVs among those ever started

Figure 2
Crude incidence rates of CKD and cumulative exposure to potentially nephrotoxic antiretrovirals

Figure 3
Unadjusted and adjusted incidence rates of CKD per year of additional exposure to potentially nephrotoxic antiretrovirals
Figure 1A
Use of potentially nephrotoxic antiretrovirals at baseline
Exposure to ARVs at/before baseline

TDF; tenofovir. ATV; atazanavir. ATV/r; ritonavir boosted atazanavir. LPV/r; ritonavir-boosted lopinavir. Other PI/r; other ritonavir-boosted protease inhibitor. IDV; indinavir. ABC; abacavir
Figure 1B

Use of potentially nephrotoxic antiretrovirals at baseline

Median exposure to ARVs among those started

N                          5844                  406                    1305                   5264                    4407                   4844                   5317
Median exposure (years) among those started (IQR)
0.7 (0.3–1.5)     1.2 (0.4–2.5)    0.9 (0.3–1.8)    1.2 (0.5–2.3)    3.4 (1.8–5.1)    4.7 (3.0–6.4)    2.0 (0.8–3.7)

TDF; tenofovir.  ATV; atazanavir.  ATV/r; ritonavir boosted atazanavir.  LPV/r; ritonavir-boosted lopinavir. Other PI/r; other ritonavir-boosted protease inhibitor.  IDV; indinavir.  ABC; abacavir
Multivariate models were adjusted for gender, race, HIV exposure group, D:A:D enrolment cohort, D:A:D participating cohort, prior CVD, age, CD4 nadir, GFR at baseline, baseline date and hepatitis B/C, AIDS diagnosis within the past 12 months, smoking status, BMI, family history of CVD, CD4, viral load, anaemia, diabetes, hypertension and cART (on/off) as time updated variables. A separate category was included for missing data where data was missing. Models were additionally adjusted for cumulative exposure to indinavir.

CKD; chronic kidney disease; confirmed (>3 months part) eGFR < 60 mL/min/1.73m²

Incidence rate ratio of CKD per additional year exposure to antiretroviral (95% CI)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Univariate</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tenofovir</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Atazanavir/r</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Lopinavir/r</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Other PI/r</td>
<td>&lt;0.0001</td>
<td>0.36</td>
</tr>
<tr>
<td>Abacavir</td>
<td>&lt;0.0001</td>
<td>0.087</td>
</tr>
</tbody>
</table>